Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other ...
) has been revised to $5.30 / share. This is a decrease of 10.86% from the prior estimate of $5.95 dated December 18, 2025. The price target is an average of many targets provided by analysts. The ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results